Member Info for Davius

Having raised £10.4m via a placing at 110p to fund expansion at the end of June, shares in RPL were suspended at 114.5p on the 5th July due to a breach of contract by its principal supplier, Safari Group Inc. Trading resumed on the 13th July at 57.5p and fell heavily, bottoming out at 33.5p on the 17th. A small rise since then has taken the share price to 35-36p now. The June placing report said: "The independent power producer with a focus on the generation of 'green' or renewable power also said it "profitably" sold both steam and electricity on June 19 from its Elmwood Park plant." Cash and assets now exceed the market capitalisation of the company and the major shareholder have over 70% of the equity. Despite the palm oil supply problems, I think this share looks like a prime candidate for recovery. I'm in at 36p.

Have had two successful trades this week, in at 65.8p and out at 82.01p, then in yesterday at 75.99p and out at 83.01p today. My take is that this is quite risky, has the potential to dive to 40p if they reveal that talks with the banks are not going well. But I will look to get back in on any drop into the mid 70s or lower. I'm running a list on advfn of where posters think the SP will close on Friday, 18 people have placed their bets and the average is now 89.44p. My tactic is to keep trades light and regular, better to take a few small 10% or 20% profits than risk one very large 50% loss.

That link was to a reference in the FT: "Carter & Carter recorded a second successive day of strong gains as the vocational training group became the centre of bid speculation, with Serco and Capita rumoured as potential bidders. Carter & Carter rose 19.5 per cent to 75p."

I think so too. Have made a buy at 1099.9p :) Could do with a swift recovery above £11 but I wouldn't be surprised if it falls a little more before recovering.

At least you won't have long to wait. They were suspended on the 27th February, so have until the 27th August to relist I believe. Quite a time to have waited to find out if you have a turkey or a golden goose. Here's hoping that they can pull off the deal.

The weary long term holders among us have seen the shares continue to decline for many months. We're waiting for news on Sampaguita, which would be expected to result in a significant rerating, if we get the service contract. There's also a suggestion of a farm-in partner, if that has been negotiated too then expect the shares to take off like a rocket. They are a couple of big IFs, but I'm content to hold and pleased to see the recovery starting. The AGM is next Monday, so the possibility of news released beforehand may well be driving the price too. Interesting that the market makers hiked it significantly before the open today, which suggests that they may have a hint of any news coming.

I've been struggling with this share, can't buy when it's rising and can't sell when it's falling. When stable no problems. Did manage an entry yesterday and sell today but it was hard work. Several buys just below market have failed, including one at 74.5p today. I'm keeping it small here though, could drop to 40p in a blink if they confirm problems with the banks. Level 2 now showing reasonable support again, but still being distorted, there are now 330K buys at 50p or less of a total of 468K buys on the system. Sells at 200K volume, 32K of those at 94p and above. So slightly in favour of buys I'd say. Huge trade today, 10.4m shares, which is 25% of the equity of the company. Lots of rumours circling of one or more possible bids, given that this company was worth £500m 4 months ago and just £31.5m now. 85p was probably a bit high to think about a re-entry, 75p might offer a good chance of profit.

Of course the reverse is also true, confirmation of an approach or putting themselves up for sale would see a leap from here. I suspect that given the huge fall in the shares since March (£12+ to 52p before rebounding) the directors would be unlikely to come out with any comment that would be further detrimental to the share price. By any accounts the shares still appear to be well undervalued, at 90p the market cap is still only £37m or so, down from £500m just 4 months ago, with a P/E for 2007 of 5.3 and still predicting growth for 2008. They must be attractive to predators at this price, the relatively high level of debt has been used to finance aquisitions which should be earnings enhancing next year. I would agree that this is risky punt at present though, up 45% on yesterdays close.

Riding strongly this morning on the back of an RNS from Thirdforce saying that they are performing to expectations. The implication is that there's nothing fundamentally wrong with the way training and apprenticeships are performing in the UK and the problems experienced by Carter and Carter are company specific and can presumably be turned around. Now up to 77.25-79p.

I put a buy order in at 58p which was missed. I watched it fall and put another in at 54p but that one failed too :( It seems whenever the SP is at the low end my broker struggles to get a trade through. My 54p order is good for the rest of the day but not looking like it will get anything like close to being hit. Potentially could crash again from here, so care needed on this one now. If they can sort out the banking options and release an update in a few days that should settle things, but a poster on advfn said he'd spoken to the company and the debt now stands at £110m, which may mean a rights issue or possibly a debt for equity swap. It sounds like the company remains profitable though and the current valuation could attract a predator. Would probably advise on taking quick profits for anyone in below 60p, don't get too greedy...

4% of the company just changed hands in a single transaction. Someone was desperate to offload or very keen to accumulate...

It seems a gross overreaction based on failure to gain a contract. But then it does come after a previous profits warning. They now say that profits will be £10.5m in the year ending this month, if the share price settles at say £1, then they are capatilised at £41m making the P/E under 4. I think that the concern will be what impact the announcement has on next years profits, if they were able to maintain the same level or higher then the shares are worth a lot more than a pound. I wonder if they'll attract a predator at these level?

Er, we've just dropped off the planet people. Despite having a modest number of shares on account it looks like a heavy loss all round. A bailed one lot at 255p and then kicked myself as they came back up. Not sure where this will stop after the auction, lots of sell instructions down to 115p, buys up to 182.5p, I think it might end up about 150p. The reason for the latest crash is that they lost the Pathways to Work contract.

It was another fall back, lol, back to around £12 again now.

Another break above £12 now. The company is likely to move into the 250 at the next reshuffle (having missed it by a day apparantly last time round) so has been predicted to move ahead for some time. However the share price has languished between around £11 and just over £12 for some weeks now. Even as I've been typing it's jumped another 20p, now at 1231-1236p. Where to from here, onwards an upwards or another fallback?

I had a punt on these a few months ago, closing out down a tad at 54p. They've been on a slow drift ever since until todays news on ASA404 which has hit them hard and caused a bit of a mini sell off, now down around 16% to 36.5p. However, the report only says that ASA404 doesn't work will all types of cancer, and that lung cancer trials by Novartis are progressing well. The hit today seems excessive given the recent slide, but although I'm a fan of recovery stocks I'm a tad wary of this one because of the general weakness in the share price since April. LONDON (Thomson Financial) - Antisoma PLC said its phase II trial of ASA404 has not produced positive results, and that ASA404 development in ovarian cancer will not be a priority. The cancer drug developer however said it is pleased with the progress made by Novartis to date with ASA404 in lung cancer. Antisoma licensed ASA404 to Novartis in April 2007. Novartis intends to start enrolling patients into a phase III trial in non-small cell lung cancer early in 2008 and to explore the potential benefits of the compound in various other solid tumours, Antisoma said.

Rebounding nicely now, 92.5-93p, buy vol 83.7K sell vol 49K.

1-1 at 88.5-90.5p, buy vol 50000, sell vol 68K. I bailed at 92p.

Yes, certainly taking a hammering, at least that justifies my 'light' entry approach when taking a T-Trade. Not much buy volume yet so not ready to take another trade, they look like they could drop a bit further to me at the moment.

Still in, ditch over half my holding on the way down at something over 15p in early June. The rest is there for the long term. Either it should multibag or crash over the next two to three years I think. Very risky share for trading though, hard to make money on short term. I still think it's a decent longer term bet though, and you can never completely discount a bid.